EARLY DATA FROM A PHASE I STUDY OF NINTEDANIB (BIBF 1120) IN ASIAN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Yen, C. [1 ]
Shen, Y. [2 ]
Shiah, H. [3 ]
Chen, J. [2 ]
Hsu, C. [2 ]
Hsu, C. [2 ]
Huang, D. C. [4 ]
Hocke, J. [5 ]
Su, W. [1 ]
Cheng, A. [2 ]
机构：
[1] Natl Cheng Kung Univ, Coll Med & Hosp, Tainan 70101, Taiwan
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Natl Hlth Res Inst, Tainan, Taiwan
[4] Boehringer Ingelheim Taiwan Ltd, Oncol, Taipei, Taiwan
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Oncol, Biberach, Germany
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：246 / 247
页数：2
相关论文
共 50 条
  • [41] Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
    Rastislav Bahleda
    Antoine Hollebecque
    Andrea Varga
    Anas Gazzah
    Christophe Massard
    Eric Deutsch
    Nadia Amellal
    Françoise Farace
    Mahmoud Ould-Kaci
    Flavien Roux
    Kristell Marzin
    Jean-Charles Soria
    British Journal of Cancer, 2015, 113 : 1413 - 1420
  • [42] Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
    Bahleda, Rastislav
    Hollebecque, Antoine
    Varga, Andrea
    Gazzah, Anas
    Massard, Christophe
    Deutsch, Eric
    Amellal, Nadia
    Farace, Francoise
    Ould-Kaci, Mahmoud
    Roux, Flavien
    Marzin, Kristell
    Soria, Jean-Charles
    BRITISH JOURNAL OF CANCER, 2015, 113 (10) : 1413 - 1420
  • [43] A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma.
    Yau, C. C.
    Chan, P.
    Pang, R.
    Chan, W.
    Cheng, P. N.
    Poon, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
    Palmer, D.
    Meyer, T.
    Chao, Y.
    Deptala, A.
    Fartoux, L.
    Feng, Y. -H.
    Graham, J.
    Lin, D. -Y.
    Ma, Y. T.
    Peck-Radosavljevic, M.
    Ross, P.
    Ryoo, B. -Y.
    Yen, C. -J.
    Hocke, J.
    Vlassak, S.
    Wenz, A.
    Loembe, A. -B.
    Cheng, A. -L.
    ANNALS OF ONCOLOGY, 2015, 26
  • [45] A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
    Dizon, Don S.
    Sill, Michael W.
    Schilder, Jeanne M.
    McGonigle, Kathryn F.
    Rahman, Zia
    Miller, David S.
    Mutch, David G.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (03) : 441 - 445
  • [46] Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
    Ikeda, Kenji
    Kudo, Masatoshi
    Kawazoe, Seiji
    Osaki, Yukio
    Ikeda, Masafumi
    Okusaka, Takuji
    Tamai, Toshiyuki
    Suzuki, Takuya
    Hisai, Takashi
    Hayato, Seiichi
    Okita, Kiwamu
    Kumada, Hiromitsu
    JOURNAL OF GASTROENTEROLOGY, 2017, 52 (04) : 512 - 519
  • [47] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Obi, Shuntaro
    Fujiyama, Shigetoshi
    Shiina, Shuichiro
    Tamai, Hideyuki
    Mochizuki, Hitoshi
    Koike, Yukihiro
    Imamura, Jun
    Yamaguchi, Takayoshi
    Saida, Isamu
    Yokosuka, Osamu
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103
  • [48] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Shuntaro Obi
    Shigetoshi Fujiyama
    Shuichiro Shiina
    Hideyuki Tamai
    Hitoshi Mochizuki
    Yukihiro Koike
    Jun Imamura
    Takayoshi Yamaguchi
    Isamu Saida
    Osamu Yokosuka
    Masao Omata
    Hepatology International, 2014, 8 : 94 - 103
  • [49] Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma
    Yang, TS
    Lin, YC
    Chen, JS
    Wang, HM
    Wang, CH
    CANCER, 2000, 89 (04) : 750 - 756
  • [50] A phase II study of sunitinib in patients with advanced hepatocellular carcinoma
    Zhu, A. X.
    Sahani, D. V.
    di Tomaso, E.
    Duda, D.
    Sindhwani, V.
    Yoon, S. S.
    Blaszkowsky, L. S.
    Clark, J. W.
    Ryan, D. P.
    Jain, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345